Health News and Scoops

As Congress and the President debate health care reform in Washington, the focus of this conversation has taken a decidedly negative turn. Somewhere in between all the committee meetings and back office dealings, health care reform became an exclusively political process, losing any focus on the actual topic of health. While the media has given health care reform front page headlines, one item lacking in this coverage is a discussion of what we can do increase our own health. Holosfitness.com has the answer.

Holosfitness.com is a free social networking website focused on fitness. The free resources available on Holosfitness.com allow individuals to get in shape, stay in shape, and lead healthy lifestyles. Never has there been a better time to take charge of your health and never has it been easier, thanks to Holosfitness.com.

Holosfitness.com is dedicated to the promotion of fitness and the need to lead healthy, active lives. The site offers dozens of free fitness videos that demonstrate a wide variety of fitness and exercise routines. Holosfitness.com encourages members to enhance their workouts with abundant diet and nutrition information posted on the website. Holosfitness.com also offers fitness blogs and commentary, including step-by-step instruction for hundreds of exercises.

Don’t let Congress and the President decide the future of your health. Take charge of your health by focusing on a balanced diet and proper exercise with the help of Holosfitness.com.

(Source) Press

A patient who had inoperable, stage 4, colon cancer is free of any detectable malignancy after using a new treatment offered by NeoPlas Innovation. All evidence of disease was gone four months after he began the lovastatin and interferon combination. Now six months into treatment, he remains free of any signs of cancer, and all previous digestive symptoms have been resolved. He is tolerating the treatment well; his only side effect is minor fatigue.

The patient, who is in his late fifties, was diagnosed with extensive cancer of the lower colon in early 2008. Initially his doctors recommended an operation to remove all the organs of his lower abdomen and pelvis. They abandoned this option, however, after determining he would have been unlikely to survive the procedure. Chemotherapy was tried but was ineffective. He visited NeoPlas Innovation’s Nashville clinic in the spring of 2009 and began its outpatient treatment.

The treatment he’s using was developed by Dr. Stephen Cantrell to battle his own malignant melanoma in 2000. Then a 33-year-old craniofacial and maxillofacial surgeon, Cantrell fought his recurring cancer with multiple surgeries, a cancer vaccine’s clinical trial and interferon. After these failed to stop the aggressive malignancy’s spread, the surgeon was told he had six weeks to live.

Refusing to accept that prognosis, he searched the medical literature for anything that was new or overlooked. He made an educated guess about trying a combination of lovastatin and interferon. Because of his terminal prognosis, he did something he would never ask of a patient. He experimented on himself with an untested treatment, keeping careful notes and becoming the guinea pig.

After four weeks of the combination, scans showed no remaining evidence of tumors from his melanoma. That was nine years ago, and there has been no evidence of cancer since. (He continues to take low, maintenance doses of both medicines.)

Patients with other cancers began requesting the new drug combination soon after Cantrell’s recovery. Continuing to see its potential in those patients, Cantrell left his surgical practice to devote his career to developing the treatment.

Patients from 28 states and four countries have now used the new combination with promising results. They are being treated for extremely aggressive cancers, such as pancreatic, colon, renal, some sarcomas, mesothelioma, melanoma and others. Eventually Cantrell hopes to implement formal clinical trials, but helping individuals remains his priority.

The treatment’s medicines have the advantage of being safe and well tolerated. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression).

(Source) Press

ANDalyze has developed an innovative heavy metals sensor platform technology for water testing powered by DNA technology. The technology replaces older time consuming methods for water testing that required knowledge and use of chemicals. The company’s product is a combination of a hand-held, ruggedized fluorimeter and a DNA sensor that gives highly accurate readings in less than two minutes.

It meets US EPA standards for accuracy and specificity of target contaminants such as lead (DNA sensors for other contaminants will be available in the near future). This solution is ideal for both government water resource authorities and industrial / corporate operations where accurate water testing is a critical requirement.

This product, the AND1000 Fluorimeter, is a breakthrough in efficiency, testing accuracy and ease-of use. No special skill or knowledge of chemistry is required to operate the device and no hazardous chemicals are used.

(Source) Press

Lumenis Inc., a global developer, manufacturer and seller of laser, light-based and radio-frequency devices for surgical, aesthetic, and ophthalmic applications, announced today the launch of the AcuPulse Fractional CO2 Laser System for aesthetic applications at the American Society of Dermatologic Surgery’s annual meeting in Phoenix this week.

“The AcuPulse now gives physicians an affordable and efficient solution to their Pulsed Fractional Skin Resurfacing needs,” said Mr. Robert Mann, General Manager of Lumenis Global Aesthetics and Dermatology. “It has been well established that pulsed CO2 lasers are superior in the treatment of wrinkles, skin dyschromias, certain types of scars, and the Lumenis’ AcuPulse brings its SuperPulse technology with the unmatched fractional scanning excellence of the Lumenis portfolio to give physicians an excellent solution for their practice,” added Mr. Mann.

“With the AcuPulse now available for Aesthetics, Lumenis will secure its leadership in the Fractional Laser market worldwide,” commented Mr. Dov Ofer, Lumenis’ Chief Executive Officer. “There are many mid and low power fractional laser systems available in the market, but Lumenis’ AcuPulse, with its SuperPulse capability, provides the lowest level of thermal damage with the same precision scanning technology already proven by its “big brother”, the UltraPulse. This system will provide the best solution for physicians at this price in the market,” added Mr. Ofer.

(Source) Press